$1.06
-0.03[-2.75%]
At close: May 16
$1.1094
0.0494[4.66%]
After Hours: 6:29PM EDT
Lineage Cell Therapeutics
(AMEX:LCTX)Latest News for Lineage Cell Therapeutics Stock (AMEX:LCTX)
Lineage Cell Therapeutics Stock (AMEX: LCTX)
Categories: All
Thursday, May 09, 2024
Monday, May 06, 2024
- Lineage Cell Therapeutics shares are trading are higher after the company announced 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study of RG6501 in patients with geographic atrophy secondary to age-related macular degeneration.Benzinga Newsdesk - May 6, 2024, 2:13PM
- HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price TargetBenzinga Newsdesk - May 6, 2024, 10:40AM
- Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation SummitBenzinga Newsdesk - May 6, 2024, 8:04AM
Friday, March 22, 2024
- Lineage Cell Therapeutics Inc May Offer And Sell Common Shares Of Up To $40M From Time To Time Through Or To B. RileyBenzinga Newsdesk - Mar 22, 2024, 4:36PM
- Lineage Cell Therapeutics Entered Into Sales Agreement With B. Riley Securities; Effective As Of March 18 Controlled Equity Offering Sales Agreement Between Co And Cantor Fitzgerald & Co. Was Terminated; On March 12 Received Written Correspondence From U.S. FDA Regarding Its Ind As Amended For OPC1; Per Correspondence, FDA Advised That Company Not Initiate Proposed Clinical Study Until It Has Received FDA Feedback; FDA Anticipates Providing Feedback By April 26, 2024Benzinga Newsdesk - Mar 22, 2024, 4:29PM
Wednesday, March 13, 2024
Friday, March 08, 2024
Thursday, March 07, 2024
- Lineage Cell Therapeutics: Q4 Earnings InsightsBenzinga Insights - Mar 7, 2024, 4:05PM
- Lineage Cell Therapeutics Q4 2023 GAAP EPS $(0.030) Beats $(0.040) Estimate, Sales $2.100M Beat $1.310M EstimateBenzinga Newsdesk - Mar 7, 2024, 4:02PM
- Earnings Scheduled For March 7, 2024Benzinga Insights - Mar 7, 2024, 4:49AM
Wednesday, March 06, 2024
Wednesday, February 14, 2024
Tuesday, February 13, 2024
Tuesday, February 06, 2024
Monday, February 05, 2024
Thursday, February 01, 2024
Tuesday, January 16, 2024
Wednesday, January 03, 2024
Friday, December 29, 2023
Monday, December 18, 2023
Thursday, November 09, 2023
Wednesday, November 08, 2023
Tuesday, October 24, 2023
Wednesday, October 11, 2023
Wednesday, September 13, 2023
Wednesday, September 06, 2023
- EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna TherapeuticsVandana Singh - Sep 6, 2023, 7:40AM
- EXCLUSIVE: Lineage Cell Therapeutics Tells Benzinga It Has Development Activities For Hypoimmune Pluripotent Cell Line For Neurology Indications Under Co.'s Partnership With Eterna TherapeuticsBenzinga Newsdesk - Sep 6, 2023, 7:40AM
Wednesday, August 16, 2023
Friday, August 11, 2023
Thursday, August 10, 2023
Wednesday, August 09, 2023
Tuesday, July 25, 2023
Monday, July 24, 2023
- Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune ResponseVandana Singh - Jul 24, 2023, 1:12PM
- HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price TargetBenzinga Newsdesk - Jul 24, 2023, 12:54PM
- Lineage Cell Therapeutics, Cancer Research UK Report Topline Phase 1 Study Results With VAC2 For Advanced Non-small Cell Lung CancerBenzinga Newsdesk - Jul 24, 2023, 8:10AM
Tuesday, July 04, 2023
- Lineage Cell Therapeutics Board Member Awarded $70K Worth of Stock OptionsBenzinga Insights - Jul 4, 2023, 11:01AM
- Lineage Cell Therapeutics Director Awarded $70K Worth of Stock OptionsBenzinga Insights - Jul 4, 2023, 11:01AM
- Lineage Cell Therapeutics Chairman Awarded $70K Worth of Stock OptionsBenzinga Insights - Jul 4, 2023, 11:01AM
- Director at Lineage Cell Therapeutics Acquires Company Stock Options Worth 50,000 SharesBenzinga Insights - Jul 4, 2023, 11:01AM
- Board Member at Lineage Cell Therapeutics Acquires Company Stock Options Worth 50,000 SharesBenzinga Insights - Jul 4, 2023, 11:01AM